ADXS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ADXS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-27), Advaxis's current share price is $0.555. Advaxis's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2023 was $236.40. Advaxis's Cyclically Adjusted PS Ratio for today is 0.00.
The historical rank and industry rank for Advaxis's Cyclically Adjusted PS Ratio or its related term are showing as below:
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Advaxis's adjusted revenue per share data for the three months ended in Mar. 2023 was $0.001. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $236.40 for the trailing ten years ended in Mar. 2023.
The historical data trend for Advaxis's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advaxis Quarterly Data | ||||||||||||||||||||
Apr18 | Jul18 | Oct18 | Jan19 | Apr19 | Jul19 | Oct19 | Jan20 | Apr20 | Jul20 | Oct20 | Jan21 | Apr21 | Jul21 | Oct21 | Jan22 | Apr22 | Jul22 | Oct22 | Mar23 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | - | 0.03 | - | - | 0.01 |
For the Biotechnology subindustry, Advaxis's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Advaxis's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Advaxis's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Advaxis's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 0.555 | / | 236.4 | |
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advaxis's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2023 is calculated as:
For example, Advaxis's adjusted Revenue per Share data for the three months ended in Mar. 2023 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Mar. 2023 (Change) | * | Current CPI (Mar. 2023) |
= | 0.001 | / | 127.3478 | * | 127.3478 | |
= | 0.001 |
Current CPI (Mar. 2023) = 127.3478.
Advaxis Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201304 | 0.000 | 98.107 | 0.000 |
201307 | 0.000 | 98.557 | 0.000 |
201310 | 0.000 | 98.536 | 0.000 |
201401 | 0.000 | 98.692 | 0.000 |
201404 | 76.923 | 100.023 | 97.937 |
201407 | 0.000 | 100.520 | 0.000 |
201410 | 0.000 | 100.176 | 0.000 |
201501 | 0.000 | 98.604 | 0.000 |
201504 | 0.000 | 99.824 | 0.000 |
201507 | 0.000 | 100.691 | 0.000 |
201510 | 0.000 | 100.346 | 0.000 |
201601 | 8.929 | 99.957 | 11.376 |
201604 | 0.000 | 100.947 | 0.000 |
201607 | 0.000 | 101.524 | 0.000 |
201610 | 113.485 | 101.988 | 141.704 |
201701 | 114.879 | 102.456 | 142.788 |
201704 | 100.735 | 103.167 | 124.345 |
201707 | 89.765 | 103.278 | 110.686 |
201710 | 51.853 | 104.070 | 63.451 |
201801 | 58.743 | 104.578 | 71.533 |
201804 | 41.595 | 105.708 | 50.110 |
201807 | 25.705 | 106.324 | 30.788 |
201810 | 21.712 | 106.695 | 25.915 |
201901 | 339.466 | 106.200 | 407.064 |
201904 | 16.054 | 107.818 | 18.962 |
201907 | 0.049 | 108.250 | 0.058 |
201910 | 0.002 | 108.577 | 0.002 |
202001 | 0.005 | 108.841 | 0.006 |
202004 | 0.330 | 108.173 | 0.388 |
202007 | 0.000 | 109.318 | 0.000 |
202010 | 0.000 | 109.861 | 0.000 |
202101 | 1.540 | 110.364 | 1.777 |
202104 | 0.893 | 112.673 | 1.009 |
202107 | 0.137 | 115.183 | 0.151 |
202110 | 0.000 | 116.696 | 0.000 |
202201 | 0.000 | 118.619 | 0.000 |
202204 | 0.137 | 121.978 | 0.143 |
202207 | 0.000 | 125.002 | 0.000 |
202210 | 0.000 | 125.734 | 0.000 |
202303 | 0.001 | 127.348 | 0.001 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of Advaxis's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Roy Golan | officer: Chief Financial Officer | 24 GOLDA MEIR ST., HOLON L3 5840425 |
Yuval Cabilly | director | C/O BIOSIGHT THERAPEUTICS, 4 HASADOT STREET, RAMAT HASHARON L3 4704348 |
Pini Orbach | director | C/O BIOSIGHT THERAPEUTICS, 3 HAYARDEN STREET, AIRPORT CITY L3 7019802 |
Bridget A Martell | director | C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268 |
Israel Biotech Fund Ii, L.p. | 10 percent owner | 4 OPPENHEIMER ST., REHOVOT L3 7670104 |
Israel Biotech Fund Gp Partners Ii, L.p. | 10 percent owner | 4 OPPENHEIMER ST., REHOVOT L3 7670104 |
Murray A Goldberg | director | 2030 MAIN STREET, SUITE 1500, IRVINE CA 92614 |
Robert J. Spiegel | director | C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025 |
Vered Bisker-leib | director | C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142 |
Israel Biotech Fund I, L.p. | 10 percent owner | 4 OPPENHEIMER ST., REHOVOT L3 7670104 |
Amoon Growth Fund Limited Partnership | 10 percent owner | 34 YERUSHALAYIM RD., RAANANA L3 4350110 |
Israel Biotech Fund Gp Partners, L.p. | 10 percent owner | 4 OPPENHEIMER ST., REHOVOT L3 7670104 |
Yair Chaim Schindel | 10 percent owner | YERUSHALAYIM ROAD 34, BEIT GAMLA ENTRANCE B, RA'ANANA L3 4350110 |
I.b.f. Management Ltd. | 10 percent owner | 4 OPPENHEIMER ST., REHOVOT L3 7670104 |
Igor Gitelman | officer: Chief Accounting Officer | 201 ROUTE 17 N., 2ND FLOOR, RUTHERFORD NJ 07070 |
From GuruFocus
By Marketwired • 07-27-2023
By Marketwired • 10-23-2023
By GuruFocusNews GuruFocusNews • 07-09-2022
By Marketwired • 08-01-2023
By GuruFocusNews GuruFocusNews • 06-29-2022
By Value_Insider Value_Insider • 10-19-2022
By Marketwired • 07-05-2023
By GuruFocusNews GuruFocusNews • 07-08-2022
By sperokesalga sperokesalga • 06-05-2023
By GuruFocusNews GuruFocusNews • 06-08-2022